Log In

 

Company Name : Boehringer Ingelheim

Friday, February 17, 2017 9:15AM IST (3:45AM GMT)

(BW)(BOEHRINGER-INGELHEIM)

US FDA Expands Approval of Tiotropium Respimat® for Maintenance Treatment of Asthma in Children


Tiotropium Respimat® (marketed as SPIRIVA® Respimat®) now approved in US as asthma maintenance treatment for people aged 6 years and older1FDA approval expands use of tiotropium Respimat® in the US to a broad age range of people across all asthma severitiesTiotropium Respimat® is currently NOT APPROVED for use in children and adolescents with asthma outside of the US


Ingelheim, Germany

Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) approved tiotropium Respimat® (marketed as SPIRIVA® Respimat®) for the long-term, once-daily maintenance treatment of people with asthma aged 6 years and older who continue to experience symptoms despite their other maintenance therapy – usually either inhaled corticosteroid (ICS) alone, or a combination of inhaled corticosteroids/long-acting beta agonists (ICS/LABA).1 This approval reflects the comprehensive tiotropium Respimat® paediatric clinical trial programme, involving 905 children aged 6-11 years, conducted by Boehringer Ingelheim.2,3,4

 

Tiotropium Respimat® is part of a class of medicines called long-acting muscarinic antagonists (LAMA) and is the only one of its kind approved for asthma. It works differently from other treatment options by complementing other maintenance therapies (usually ICS/LABA) to open the airways, which helps people breathe better and reduces asthma attacks, also known as exacerbations.

 

“This FDA approval expands the US indication for tiotropium Respimat® to a broad range of patients, including children, adolescents and adults in the US who may suffer from symptomatic asthma despite taking other maintenance therapies,” said Dr William Mezzanotte, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim. “The expansive paediatric programme within the comprehensive UniTinA-asthma® clinical trial programme, reflects the ongoing commitment of Boehringer Ingelheim to providing innovative solutions for children and adults living with asthma and other serious respiratory diseases.”

 

In the comprehensive, large-scale UniTinA-asthma® clinical trial programme, tiotropium Respimat® demonstrated proven efficacy and safety as an add-on therapy for children, adolescents and adults with asthma.1,5,6,7,8,9,10,11,12,13

 

Tiotropium Respimat® is delivered via Respimat®, the only inhaler that actively* delivers a propellant-free mist, meaning a person just needs to take a slow deep breath in for the medication to go deep into the lungs.14,15,16,17,18,19,20

 

Previously, in September 2015, tiotropium Respimat® was approved in the US for the long-term, once-daily, prescription maintenance treatment of asthma in people aged 12 and older.1 Tiotropium Respimat® was approved in the EU in 2014 as an add-on therapy for adults (aged 18 and older) with asthma.

 

For more information please visit http://www.boehringer-ingelheim.com/press-release/ASTHMA-FDA-Expanded_Approval_of_Tiotropium_Respimat®

 

Intended audiences:

 

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products varies from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

 

-----------------

 

SPIRIVA® Respimat® is currently NOT APPROVED for use in children and adolescents under 18 years of age in the EU. SPIRIVA® Respimat® has been approved for use in asthma in over 50 countries, including in the EU, U.S. and Japan. The label varies by country. Please refer to the local product information.

 

* Respimat® delivers a metered dose of medication in a mist at the push of a button not requiring the force from the patient’s inhalation

 

 

 

 


Click here for Media Contact Details
CONTACTS : Boehringer Ingelheim Corporate Communications Media + PR Dr. Kristin Jakobs Phone: +49 6132 77 144553 Mobile: +49 1516 89 47444 Fax: +49 6132 77 6601 Email: press@boehringer-ingelheim.com

More News from Boehringer Ingelheim

18/02/2018 1:59PM

Systemic Sclerosis World Congress: Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease

'More Than Scleroderma: The Inside Story' provides real-life stories and education about the life-threatening disease New and truly inspiring patient stories are revealed Help raise awareness of this ...

04/01/2018 6:21PM

Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€

Boehringer Ingelheim announced an increase in funding for its corporate venture fund, known as the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million. The additional funds will be used to invest in ...

11/12/2017 7:30PM

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017

2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External ...

Similar News

20/02/2018 1:15PM

Herbalife Nutrition India Launches Strawberry Flavour of Dinoshake Nutritional Children's Drink Mix

Herbalife Nutrition, a global nutritional company, announced it is doubling the tastes available for Dinoshake Nutritional Children’s Drink Mix in Indai, adding Strawberry flavour to accompany the delicious Dinoshake ...

No Image

20/02/2018 1:06PM

बेस्ट क्योर फाउंडेशन (बीसीएफ) और टीमबेस्ट कंपनीज अंतरराष्ट्रीय स्तर पर मुनाफा न कमाने वाली/गैरसरकारी बेस्ट क्योर हेल्थ सिस्टम और बेस्ट क्योर इंश्योरेंस की शुरुआत कर रहे हैं ताकि 10 ट्रिलियन अमेरिकी डॉलर से ज्यादा की अंतरराष्ट्रीय हेल्थकेयर डिलीवरी सिस्टम को बहुत बेहतर और कम महंगा बनाया जा सके

कृष्णन सुथांथिरण ने 2007 में बेस्ट केयर फाउंडेशन (मुनाफ न कमाने वाले एक गैरसरकारी संगठन) की स्थापना की ताकि उच्च गुणवत्ता वाले हेल्थकेयर और उच्च शिक्षा को किफायती बनाया जा सके और अंतरराष्ट्रीय स्तर पर हर ...